Jazz Pharmaceuticals plc – Shares Down 4.8% After Analyst Downgrade (JAZZ)
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) traded down 4.8% during mid-day trading on Thursday after FBR Capital Markets lowered their price target on the stock from $214.00 to $213.00, Analyst Ratings Network.com reports. The stock traded as low as $135.00 and last traded at $135.99, with a volume of 1,395,611 shares traded. The stock had previously closed at $142.84.
JAZZ has been the subject of a number of other recent research reports. Analysts at Leerink Swann raised their price target on shares of Jazz Pharmaceuticals plc – from $177.00 to $181.00 in a research note on Wednesday. They now have an “outperform” rating on the stock. Finally, analysts at Buckingham Research initiated coverage on shares of Jazz Pharmaceuticals plc – in a research note on Wednesday, July 23rd. They set a “buy” rating and a $215.00 price target on the stock. Six analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Jazz Pharmaceuticals plc – has an average rating of “Buy” and a consensus target price of $174.05.
The stock’s 50-day moving average is $147.1 and its 200-day moving average is $145.3. The company has a market cap of $8.061 billion and a P/E ratio of 105.57.
Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) last announced its earnings results on Tuesday, August 5th. The company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.92 by $0.13. The company had revenue of $291.23 million for the quarter, compared to the consensus estimate of $273.39 million. During the same quarter in the previous year, the company posted $1.43 earnings per share. The company’s revenue for the quarter was up 39.8% on a year-over-year basis. On average, analysts predict that Jazz Pharmaceuticals plc – will post $8.17 earnings per share for the current fiscal year.
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.